Evidence map›Paper›PMID 41757872›Full record

ArticleBipolar disorders2026

SGLT2 Inhibitors Associated With Improved Kidney Function in Lithium-Treated Patients With Mood Disorders: A Real-World Historical Cohort Study.

Mete Ercis, Idil Tarikogullari, Vanessa K Pazdernik, Maria L Gonzalez Suarez, Raman Baweja, Alessandro Miola, Osama A Abulseoud, Jonathan G Leung, Susan L McElroy, Alfredo B Cuellar-Barboza and 4 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Bipolar disorders, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

14 authors.

Mete ErcisDepartment of Psychiatry & Psychology, Mayo Clinic, Rochester, Minnesota, USA.
Idil TarikogullariDepartment of Psychiatry & Psychology, Mayo Clinic, Rochester, Minnesota, USA.
Vanessa K PazdernikDepartment of Quantitative Health Sciences, Mayo Clinic, Rochester, Minnesota, USA.
Maria L Gonzalez SuarezDivision of Nephrology and Hypertension, Mayo Clinic, Rochester, Minnesota, USA.
Raman BawejaDepartment of Psychiatry and Behavioral Health, Pennsylvania State College of Medicine, Hershey, Pennsylvania, USA.
Alessandro MiolaDepartment of Psychiatry & Psychology, Mayo Clinic, Rochester, Minnesota, USA.ORCID 0000-0002-2513-2718
Osama A AbulseoudDepartment of Psychiatry and Psychology, Mayo Clinic Arizona, Phoenix, Arizona, USA.
Jonathan G LeungDepartment of Pharmacy, Mayo Clinic, Rochester, Minnesota, USA.ORCID 0000-0003-3836-9375
Susan L McElroyLindner Center of HOPE Research Institute, Mason, Ohio, USA.
Alfredo B Cuellar-BarbozaDepartment of Psychiatry & Psychology, Mayo Clinic, Rochester, Minnesota, USA.
Michael J GitlinDepartment of Psychiatry and Biobehavioral Sciences, Jane and Terry Semel Institute for Neuroscience and Human Behavior, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, California, USA.
Aysegul OzerdemDepartment of Psychiatry & Psychology, Mayo Clinic, Rochester, Minnesota, USA.
Mark A FryeDepartment of Psychiatry & Psychology, Mayo Clinic, Rochester, Minnesota, USA.ORCID 0000-0001-6997-4215
Balwinder SinghDepartment of Psychiatry & Psychology, Mayo Clinic, Rochester, Minnesota, USA.ORCID 0000-0001-7062-8192

Funding

Mayo Clinic Center for Clinical and Translational Science (CCaTS UL1 Supplement - Dr. Timothy Curry)UL1TR002377 · NCATS · MAYO CLINIC ROCHESTER · PI VESNA D GAROVIC · 2017 to 2026
$78.4M
Institutional Career Development CoreKL2TR002379 · NCATS · MAYO CLINIC ROCHESTER · PI NILUFER ERTEKIN-TANER · 2017 to 2026
$14.9M
National Center for Advancing Translational Sciences (NCATS) UL1TR002377NCATS NIH HHS KL2 TR002379NCATS NIH HHS UL1 TR002377
6 · The paper itself

Abstract

introductionSodium-glucose cotransporter-2 inhibitors (SGLT2i), initially developed for type 2 diabetes, have shown promise in improving renal outcomes in patients with and without diabetes. However, their effect on lithium-associated kidney dysfunction remains unknown.

methodsThis historical cohort study included patients from Mayo Clinic (2001-2023) with mood disorders who received lithium for ≥ 6 months and later used SGLT2i for ≥ 1 month. Data on SGLT2i use and lithium treatment were extracted from electronic health records. Serum creatinine values were used to calculate estimated glomerular filtration rate (eGFR) trajectories. Linear mixed-effects models with piecewise linear splines were used to estimate eGFR slopes before and after SGLT2i initiation, adjusted for age and sex.

resultsFifty-six patients (mean age 57.4 years, 46.4% female), predominantly with bipolar disorder (87.5%), were included. The mean eGFR, measured nearest to SGLT2i initiation, was 77.9 ± 26.0 mL/min/1.73 m

conclusionSGLT2i treatment was associated with a significant improvement in eGFR trajectory in patients with mood disorders who received long-term lithium therapy. These findings suggest a potential role for SGLT2is in mitigating lithium-associated kidney dysfunction and highlight the need for randomized controlled trials in this population.

Indexed as

Antimanic AgentsBipolar DisorderGlomerular Filtration RateKidneyLithiumLithium CompoundsMood DisordersSodium-Glucose Transporter 2 InhibitorsAgedCohort StudiesCreatinineFemaleHumansMaleMiddle AgedAntimanic AgentsCreatinineLithiumLithium CompoundsSodium-Glucose Transporter 2 Inhibitorsbipolar disordercreatininekidneylithiummood disorderssodium‐glucose transporter 2 inhibitors

Identifiers

PMID41757872
PMCPMC13005608

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.